Seminar

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

22 November 2017: Seminar on Biosimilars & Competition Law

16.10.2017 NL law

On Wednesday 22 November 2017, Stibbe will organise a seminar on Biosimilars & Competition Law in Brussels. This seminar will be co-organized by competition lawyers from Stibbe and competition economists from CRA so as to cover both legal and economic angles relevant to this increasingly important field. 

Given the ever increasing economic significance of biologics in the pharmaceutical space – as well as signals from regulators that this field will come into focus shortly – it  is time to explore the implications of the competition rules for business behavior in this area. This includes a discussion of the following topics/questions: 

  • What can we expect from competition authorities in this space?
  • To what extent do the competition law principles developed for synthetic drugs apply to the biological space?
  • How does this play out in the context of life cycle management?  
  • What stance do authorities take in merger control cases involving biologics?
  • What about pricing strategies? Is there more reason for concern following cases like Aspen (EU) and Pfizer (UK)?

Our intention is to go beyond scratching the surface on these topics in order to provide guidance for pharmaceutical companies in an area which we feel is receiving insufficient attention in the competition law domain. 

For more information and to register, please send an email to: StibbeEvents@Stibbe.com.

A provisional program can be found below: 

  • 12:00 - 12:30: Registration
  • 12:30 - 12:45:  Introduction by chair - Stibbe/CRA
  • 12:45 - 13:15: Keynote speech by Paul Paul Csiszár, Director of "Basic Industries, Manufacturing and Agriculture", responsible for the Commission’s pharma unit
  • 13:15 - 13:45: Industry trends in biosimilars - Tim Wilsdon, CRA  
  • 13:45 - 14:30: Biologics in EU merger control: current status and likely issues in the future - Stibbe
  • 14:30 - 15:00: Break
  • 15:00 - 15:45: Competition law boundaries of life cycle management strategies: application to the biologics space - Stibbe
  • 15:45 - 16:30: Pricing practices & antitrust: law and economics - Raphaël De Coninck, CRA
  • 16:30 - 16: 45: Closing
  • 16:45 - 17:30: Drink

When: 22 November 2017 from 12.00 -17.30.

Where: Stibbe office: Central Plaza - Loksumstraat 25 Rue de Loxum - 1000 Brussels

stibbe_logo_background_01    logo - CRA

 

Team

Related news

03.08.2022 EU law
Gotta catch ‘em all? Upward referral of ‘killer acquisitions’ upheld

Short Reads - Companies involved in intended or completed M&A transactions falling below EU and national merger notification thresholds should beware that their deals may still catch the European Commission’s eye. The General Court has upheld the Commission’s decision to accept a national referral request regarding Illumina’s acquisition of Grail: a transaction not triggering any of the notification thresholds within the EEA.

Read more

28.07.2022 NL law
Purely commercial interest also a legitimate interest? Council of State leaves the question unanswered.

Short Reads - On 27 July 2022, the Council of State confirmed that the Dutch Data Protection Authority wrongly imposed a €575,000 fine on VoetbalTV. But the Council did not answer the question whether the AP rightly or wrongly believes that a purely commercial interest cannot be a legitimate interest within the meaning of the General Data Protection Regulation.

Read more

06.07.2022 NL law
Highest Dutch court: the postman may still ring twice?

Short Reads - The Dutch Minister of Economic Affairs and Climate Policy was wrong to unblock the ACM’s prohibited merger between postal operators PostNL and Sandd on grounds of public interest. According to the Trade and Industry Appeals Tribunal (CBb), the Minister cannot substitute the ACM’s assessment for its own when considering public interest reasons. Since the Minister did do so in this particular case, the CBb annulled the Minister’s merger clearance.

Read more

28.07.2022 NL law
Zuiver commercieel belang ook gerechtvaardigd belang: Raad van State laat zich er niet over uit

Short Reads - Op 27 juli 2022 heeft de Raad van State bevestigd dat de Autoriteit Persoonsgegevens onterecht een boete van € 575.000 aan VoetbalTV heeft opgelegd. De hoop bestond dat de Afdeling antwoord zou geven op de vraag of de AP terecht of onterecht meent dat een zuiver commercieel belang géén gerechtvaardigd belang kan zijn in de zin van de Algemene Verordening Gegevensbescherming. Het antwoord op deze vraag blijft echter uit.  

Read more

06.07.2022 NL law
Foreign Subsidies Regulation crosses the finish line

Short Reads - On 30 June 2022, the European Parliament and the European Council reached agreement on the final text of the Foreign Subsidies Regulation. Adding to the regulatory burdens, this Regulation creates a notification obligation for companies that receive subsidies from non-EU governments in transactions or public procurement procedures. 

Read more